Illinois CancerCare (Carthage)

Carthage, IL

Sorting 3 by

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 3

Accepting patients

Triplet Induction + 1 or 2-Drug Maintenance

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Randomization
  • Phase 3
2 hidden based on your filters. Show All